Talk:Monoclonal antibody therapy

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Rewrite

The information on this page was very, very good, almost too good. The main problems that I found and fixed were:

Too much detail- not enough background.
Talked only about cancer drugs, neglected all of the other Mabs.
Way too many references (107), it is almost as if someone copied a journal article into here. Much of the same background information can be found in textbooks (one source).
Poor layout and "wiki-syntax" throughout, also a bit "wordy".

I have removed some extraneous detail that does not belong in this article, created a summary table and included all the Mabs I could find, moved a lot of the specific cancer Mab info to cancer immunotherapy. I have also fixed the wiki-syntax and presented a more reasonable flow of information. Cheers--DO11.10 23:51, 30 October 2006 (UTC)[reply]

From article: Monoclonal antibody therapy of cancer

with regards to an article in the times (march 19th 2006) what was the monoclonal antibody tested? any information about this trial wopuld be appreciated

That trial was on the monoclonal antibody "TGN 1412" (anti-CD28), there is an article on wikipedia about it.

Page recreated!!??

This article was recreated from material in the article Monoclonal antibody therapy, which had some serious problems, and that I have already cleaned up. The information in this article is already repeated in both articles Monoclonal antibody therapy and Cancer immunotherapy, and this page will be redirected to "Monoclonal antibody therapy" unless you can come up with a very compelling reason why it should not.--DO11.10 06:29, 19 March 2007 (UTC)[reply]

Having heard nothing, I am now redirecting this page (Monoclonal antibody therapy of cancer) to "Monoclonal antibody therapy" as all information is redundant..--DO11.10 00:17, 26 March 2007 (UTC)[reply]

Image:MonoclonalAb.jpg

This bot has detected that this page contains an image, Image:MonoclonalAb.jpg, in a raster format. A replacement is available as a Scalable vector graphic (SVG) at File:Monoclonal antibodies.svg. If the replacement image is suitable please edit the article to use the vector version. Scalable vector graphics should be used in preference to raster for images that can easily represented in a vector graphic format. If this bot is in error, you may leave a bug report at its talk page Thanks SVnaGBot1 (talk) 14:21, 30 April 2009 (UTC)[reply]

Updating list

Suggest updating list of approved therapies. (http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted)

This includes including: Imatinib mesylate, Dasatinib, Nilotini, Lapatinib (Tykerb®), Gefitinib (Iressa®), Erlotinib, Sorafenib, Sunitinib, Pazopanib, and others. —Preceding unsigned comment added by Raulcereno (talk • contribs) 14:24, 15 September 2010 (UTC)[reply]

Are there different mechanisms

Some Ab might act by just blocking or activating cell receptors (and could be replaced by antibody mimetics? or antibody fragments), others might activate components of the immune system. Is it worth clarifying ? - Rod57 (talk) 12:42, 11 December 2015 (UTC)[reply]

Monoclonal antibody#Examples of therapeutic monoclonal antibodies has an overlapping table that has a mechanism column showing some binding to cell receptors and others to ligands. - Rod57 (talk) 13:36, 18 October 2016 (UTC)[reply]

Non-FDA approvals

The table of FDA approved could be extended with another column for EU approval date ? - Rod57 (talk) 12:50, 11 December 2015 (UTC)[reply]

How do their terminal half-lives compare

Can we say if they all have a similar terminal half-life (eg because of a common clearance mechanism?) or what the differences depend on (eg surface sugars, chimeric/humanised, antibody subtype, other attached groups eg in antibody-drug conjugates, ...) ? - Rod57 (talk) 13:03, 18 October 2016 (UTC)[reply]

The topic of antibodies pharmacokinetics is very interesting, I suggest this topic should be added later. As for 2022, Long-acting antibody(LAAB) for COVID19 prevention is approved in phase III clinical trial and also emergency use in some circumstances. For more information please refer to

https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html

Konrawit13 (talk) 02:16, 22 July 2022 (UTC)[reply]